Condition: Iliac Aneurysm · Aortic Aneurysm, Abdominal · Sponsor: Archo Medical S.A
The goal of this clinical trial is to evaluate the safety, performance, and Preliminary effectiveness of the iHub endoprosthesis system in treating iliac artery aneurysms in adult patients requiring endovascular repair. The study population includes both male and female adults over 18 years of age who meet the inclusion criteria for endovascular treatment of iliac artery aneurysms. The main questions it aims to answer are: Is the iHub stent-graft system safe for use in patients with iliac artery aneurysms? Does the iHub system demonstrate adequate technical performance and sustained patency over a 12-month follow-up period? Participants will undergo a minimally invasive endovascular procedure to implant the iHub endoprosthesis system. The device is designed to preserve internal iliac artery flow while excluding the aneurysmal segment. Participants will: Undergo pre-screening evaluations including clinical examination, laboratory tests, and imaging (CT angiography and ultrasound). Undergo endovascular implantation of the iHub device. Attend follow-up visits at 30, 90, 180, and 360 days post-implant to assess clinical outcomes and device performance.
This description comes directly from the study's public registry record.
Suzan X Lima · 5548988092141 · regulatorio@archomedical.com
Marcela M Dutra · 5554898004664 · mdutra.regulatorio@gmail.com
Always discuss trial participation with your own doctor first.
| Instituto de Ensino e Pesquisa Dr. Irineu May Brodbeck - Hospital Baía Sul S/A | Florianópolis, Santa Catarina, Brazil | Recruiting |
| Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP | São Paulo, São Paulo, Brazil | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07005141